Clinical trials: TNF Alpha
Crohn Disease
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 [NCT00552058].
- Trial name
- NCT00552344
- Testing
- Cimzia
- Where
- 100 sites in United States, Australia and 16 more
- Volunteers
- 403 people
- Sponsor
- UCB BIOSCIENCES GmbH
Rheumatoid Arthritis
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding…
- Trial name
- NCT03001219
- Testing
- Anti-TNF-alpha, Methotrexate, RO7123520
- Where
- 81 sites in United States, Argentina and 9 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in an experiment to see if it may be useful in preventing relapse of Crohn's disease after surgical resection.
- Trial name
- NCT01190839
- Testing
- Infliximab
- Where
- 142 sites in United States, Australia and 12 more
- Volunteers
- 297 people
- Sponsor
- Janssen Biotech, Inc.
Arthritis, Psoriatic
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active Psoriatic Arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- Discover-1 (NCT03162796)
- Testing
- Guselkumab
- Where
- 95 sites in United States, Australia and 11 more
- Volunteers
- 383 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Observation of Treatment With Certolizumab Pegol in Daily Practice
This is an observational, non-interventional, non-comparative, post-authorization safety study to evaluate efficacy and long-term safety of Cimzia in adult patients with RA in need of treatment with a biological product.
- Trial name
- FasT (NCT01069419)
- Where
- 163 sites in Germany
- Volunteers
- 1,117 people
- Sponsor
- UCB Pharma GmbH
Crohn's Disease
Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection…
- Trial name
- NCT01714726
- Testing
- MEDI2070
- Where
- 80 sites in United States, Canada and 7 more
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy
People affected by rheumatoid arthritis are often suffering from fatigue and decreased QOL. In this study we are measuring the impact of SC biologics on these parameters.
- Trial name
- NCT01521884
- Testing
- SC anti-TNF
- Where
- Belgium
- Volunteers
- 62 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid…
- Trial name
- NCT00361335
- Testing
- Golimumab, Methotrexate
- Where
- 72 sites in United States, Argentina and 13 more
- Volunteers
- 643 people
- Sponsor
- Centocor, Inc.
Rheumatoid Arthritis
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
The primary objective of this study is to evaluate the efficacy of atacicept compared to placebo in the treatment of signs and symptoms in a subject population with active rheumatoid arthritis (RA), inadequate response to…
- Trial name
- AUGUST II (NCT00595413)
- Testing
- Atacicept: with loading dose, Atacicept, Adalimumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 311 people
- Sponsor
- EMD Serono
Ulcerative Colitis
Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC
To evaluate the efficacy and safety of Neihulizumab (ALTB-168) administered intravenously in patients with moderate to severe active ulcerative colitis who are refractory or intolerant to anti-Tumor Necrosis Factor α and/or…
- Trial name
- TNF (NCT03298022)
- Testing
- ALTB-168
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- AltruBio Inc.
Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy of ustekinumab, in adult anti-TNF(alpha) refractory participants with active radiographic axial spondyloarthritis (AxSpA), as measured by the reduction in signs and symptoms of…
- Trial name
- NCT02438787
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Where
- 148 sites in United States, Argentina and 17 more
- Volunteers
- 315 people
- Sponsor
- Janssen Research & Development, LLC
Juvenile Idiopathic Arthritis
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to…
- Trial name
- NCT01230827
- Testing
- CNTO 148 (Golimumab), Methotrexate
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 173 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate and have had an inadequate response to a…
- Trial name
- OSKIRA - 3 (NCT01197755)
- Testing
- fostamatinib
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 323 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
- Trial name
- NCT03760003
- Testing
- ABX464 100 mg, ABX464 50 mg, ABX464 25 mg
- Where
- 130 sites in United States, Austria and 15 more
- Volunteers
- 355 people
- Sponsor
- Abivax S.A.
Axial Spondyloarthrithis, Ankylosing Spondylitis
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
Patients receive study drug for one year (Part A). If, after the initial run-in phase, a sustained remission is reached they will be randomly split into one of three dose groups for another year (Part B).
- Trial name
- C-OPTIMISE (NCT02505542)
- Testing
- Certolizumab Pegol
- Where
- 108 sites in United States, Belgium and 12 more
- Volunteers
- 736 people
- Sponsor
- UCB BIOSCIENCES GmbH
Axial Spondyloarthritis
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy of ustekinumab, in adult participants with active radiographic axial spondyloarthritis (AxSpA), who are naive to anti-TNF alpha agents, as measured by the reduction in signs and…
- Trial name
- NCT02437162
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Where
- 57 sites in United States, Czechia and 5 more
- Volunteers
- 347 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Psoriatic
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
The purpose of this study is to evaluate the efficacy (improvement of signs and symptoms) and safety of ustekinumab in patients with psoriatic arthritis.
- Trial name
- NCT01077362
- Testing
- ustekinumab 45 mg, ustekinumab 90 mg
- Where
- 80 sites in United States, Austria and 8 more
- Volunteers
- 312 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Mucosal Healing Study in Crohn's Disease (CD)
The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohn's disease.
- Trial name
- MUSIC (NCT00297648)
- Testing
- Certolizumab pegol
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 89 people
- Sponsor
- UCB Pharma
Crohn's Disease
Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease
A Phase 2b study to evaluate the efficacy and safety of brazikumab (MEDI2070) in participants with moderate to severe Crohn's disease who have failed or are intolerant to anti-tumor necrosis factor-alpha (anti-TNFα) therapy.
- Trial name
- NCT02574637
- Testing
- Brazikumab IV Infusion, Brazikumab SC Injection
- Where
- 97 sites in United States, Australia and 10 more
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Crohn's Disease
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581].
- Trial name
- Welcome2 (NCT00333788)
- Testing
- Certolizumab pegol (CDP870)
- Where
- 65 sites in United States, Austria and 10 more
- Volunteers
- 233 people
- Sponsor
- UCB Pharma